Kinase News and Research

RSS

New combination therapy holds promise for treating HER2-positive breast cancer

Resistance to therapy is a major problem in the cancer field. Even when a treatment initially works, the tumors often find ways around the therapy.

10 Apr 2015

Winners of GSA poster awards announced at 56th Annual Drosophila Research Conference

The Genetics Society of America (GSA) and the Drosophila research community are pleased to announce the winners of the GSA poster awards at the 56th Annual Drosophila Research Conference, which took place in Chicago, IL, March 4-8, 2015.

10 Apr 2015

Newly approved drug for rare blood cancer shows sustained benefit for 2 years

The most recent results from a clinical trial show that ibrutinib, a newly approved drug for Waldenstrom's Macroglobulinemia, continued to control the rare blood cancer, with 95 percent of patients surviving for two years, report investigators from Dana-Farber Cancer Institute.

10 Apr 2015

New blood test may more accurately identify biomarkers for Parkinson's disease

A new blood test may more accurately identify blood signatures, or biomarkers, for Parkinson's disease (PD), according to a new study published in the journal Movement Disorders.

7 Apr 2015

Common cancers deform mitochondria to create conducive environment for tumor growth

In a breakthrough in the understanding of how cancer does its deadly work, researchers at the University of Virginia School of Medicine have shown that many cancers - including nearly all pancreatic cancers - enslave and deform mitochondria, the powerhouses of cells, to create an environment more conducive to tumor growth.

7 Apr 2015

Nanoparticle technique inhibits tumor growth, prolongs survival in animal models

Delving into the world of the extremely small, researchers are exploring how biodegradable nanoparticles can precisely deliver anticancer drugs to attack neuroblastoma, an often-deadly children's cancer.

3 Apr 2015

Pseudogenes may play role in cancer development, shows study

Pseudogenes, a sub-class of long non-coding RNA (lncRNA) that developed from the genome's 20,000 protein-coding genes but lost the ability to produce proteins, have long been considered nothing more than genomic "junk." Yet the retention of these 20,000 mysterious remnants during evolution has suggested that they may in fact possess biological functions and contribute to the development of disease.

3 Apr 2015

Low doses of imatinib drug can push immune system to combat bacterial infections

Low doses of the anti-cancer drug imatinib can spur the bone marrow to produce more innate immune cells to fight against bacterial infections, Emory researchers have found.

1 Apr 2015

Selvita commences IND-enabling studies for its first oncology drug candidate

Selvita, the largest drug discovery company in Central and Eastern Europe, announced today that it is commencing IND-enabling studies for SEL24 project, the company’s first oncology drug candidate.

1 Apr 2015

Less-toxic drug combined with fasting may kill cancer cells

Fasting in combination with chemotherapy has already been shown to kill cancer cells, but a pair of new studies in mice suggests that a less-toxic class of drugs combined with fasting may kill breast, colorectal and lung cancer cells equally well.

31 Mar 2015

Patient with severe Alzheimer's shows promising benefits during treatment with Bryostatin drug

Researchers at the Blanchette Rockefeller Neurosciences Institute and the Marshall University Joan C. Edwards School of Medicine announced their findings from a new study entitled, "PSEN1 Variant in a Family with Atypical AD." An Alzheimer patient with very severe disease, genetically confirmed to have a known variant of PSEN1, showed promising benefits during treatment with the drug Bryostatin 1.

30 Mar 2015

Caris Life Sciences study may have potentially significant benefit in patients with uterine cancer

Caris Life Sciences today announced the presentation of a study that found drugs targeting specific pathways may have potentially significant benefit in a select subset of patients with uterine cancer. The study results were highlighted today in an oral presentation in a Plenary Session at the Society of Gynecologic Oncology 2015 Annual Meeting on Women's Cancer in Chicago, Ill.

30 Mar 2015

AACR to honor Lewis C. Cantley with Princess Takamatsu Memorial Lectureship

The American Association for Cancer Research will honor Lewis C. Cantley, PhD, with the ninth annual Princess Takamatsu Memorial Lectureship at the AACR Annual Meeting 2015, to be held in Philadelphia, April 18-22.

29 Mar 2015

TSRI scientists identify enzyme that maintains healthy periods of inactivity in HSCs to prevent anemia

Stem cells can generate any type of cell in the body, but they are inactive most of the time—and for good reason. When stem cells become too active and divide too often, they risk acquiring cell damage and mutations. In the case of blood stem cells (also called hematopoietic stem cells or HSCs), this can lead to blood cancers, a loss of blood cells and an impaired ability to fight disease.

26 Mar 2015

Personalized gene therapy to fight against cancer

The fight to treat cancer and eradicate tumors will likely benefit from a new set of treatments if early development phases continue to show promise, according to Kalorama Information. The healthcare market research publisher stated that gene therapies that are able to deliver genetic material to a specific cell population or tumor that will result in the destruction of the tumor.

25 Mar 2015

New approach to treating B-ALL tumour disease

B cell acute lymphoblastic leukaemia, or B-ALL, is the most common tumour disease in children and also occurs in adults. It develops when signalling pathways in immature B cells, or pre-B cells, are dysregulated. Prof. Dr. Markus Müschen from the University of California in San Francisco, USA, and his team worked together with the BIOSS researchers Prof. Dr. Hassan Jumaa and Prof. Dr. Michael Reth to find a new approach for treating the B-ALL tumour disease.

25 Mar 2015

Brain-somatic-activating mutations in MTOR cause focal cortical dysplasia type II

Epilepsy is a brain disorder that afflicts more than 50 million people worldwide. Many epilepsy patients can control their symptoms through medication, but about 30% suffer from intractable epilepsy and are unable to manage the disease with drugs. Intractable epilepsy causes multiple seizures, permanent mental, physical, and developmental disabilities, and even death.

25 Mar 2015

Kinase News and Research

New combination therapy holds promise for treating HER2-positive breast cancer

Winners of GSA poster awards announced at 56th Annual Drosophila Research Conference

Newly approved drug for rare blood cancer shows sustained benefit for 2 years

New blood test may more accurately identify biomarkers for Parkinson's disease

Common cancers deform mitochondria to create conducive environment for tumor growth

Nanoparticle technique inhibits tumor growth, prolongs survival in animal models

Pseudogenes may play role in cancer development, shows study

Low doses of imatinib drug can push immune system to combat bacterial infections

Selvita commences IND-enabling studies for its first oncology drug candidate

Less-toxic drug combined with fasting may kill cancer cells

Patient with severe Alzheimer's shows promising benefits during treatment with Bryostatin drug

Caris Life Sciences study may have potentially significant benefit in patients with uterine cancer

AACR to honor Lewis C. Cantley with Princess Takamatsu Memorial Lectureship

TSRI scientists identify enzyme that maintains healthy periods of inactivity in HSCs to prevent anemia

Personalized gene therapy to fight against cancer

New approach to treating B-ALL tumour disease

Brain-somatic-activating mutations in MTOR cause focal cortical dysplasia type II

Laboratory criteria for CML deep molecular response reviewed

Fourth-line bosutinib ‘appropriate’ after prior CML treatment failure, intolerance

ItpkB enzyme regulates stem cells function to prevent cancer, anemia

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News